Rapivab
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $2,350 | 3 | 0 |
| 2020 | $15,932 | 4 | 0 |
| 2019 | $41,091 | 17 | 0 |
| 2018 | $111,830 | 31 | 0 |
| 2017 | $82,895 | 44 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $254,080 | 98 | 100.0% |
| Food and Beverage | $18.15 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, multicenter, single-arm, open-label, study to evaluate the safety, pharmacokinetics and effectiveness of intravenous permavir in elderly subjects with acute uncomplicated influenza infections and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications. | BioCryst Pharmaceuticals, Inc. | $111,830 | 0 |
| A Phase 3, multicenter, single-arm, open-label, study to evaluate the safety, pharmacokinetics and effectiveness of intravenous permavir in elderly subjects with acute uncomplicated influenza infections and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications | BioCryst Pharmaceuticals, Inc. | $82,877 | 0 |
| A phase 3, multicenter, single-arm, open-label, study to evaluate the safety, pharacokinetics and effectiveness of intravenous peramivir in elderly subjects with acute uncomplicated influenxa infection at higher risk for influenza complications. | BioCryst Pharmaceuticals, Inc. | $41,091 | 0 |
| A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza | BioCryst Pharmaceuticals, Inc. | $15,932 | 0 |
| A Phase 3 Randomized Open Label Active-controlled Study to Evaluate the Safety Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza | BioCryst Pharmaceuticals, Inc. | $2,350 | 0 |
Top Doctors Receiving Payments for Rapivab
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cincinnati, OH | $254,080 | 98 |
| , MD | Infectious Disease | Long Beach, CA | $18.15 | 1 |
Manufacturing Companies
- BioCryst Pharmaceuticals, Inc. $254,080
- Seqirus USA Inc $18.15
Product Information
- Type Biological
- Total Payments $254,098
- Total Doctors 1
- Transactions 99
About Rapivab
Rapivab is a biological associated with $254,098 in payments to 1 healthcare providers, recorded across 99 transactions in the CMS Open Payments database. The primary manufacturer is BioCryst Pharmaceuticals, Inc..
Payment data is available from 2017 to 2021. In 2021, $2,350 was paid across 3 transactions to 0 doctors.
The most common payment nature for Rapivab is "Unspecified" ($254,080, 100.0% of total).
Rapivab is associated with 5 research studies, including "A Phase 3, multicenter, single-arm, open-label, study to evaluate the safety, pharmacokinetics and effectiveness of intravenous permavir in elderly subjects with acute uncomplicated influenza infections and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications." ($111,830).